Physician profile
Mark Stephen Umphrey
NPI 1871931162
$5,056.41
in general payments reported to CMS, 2019-2025
26 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $614 · 2021: $902 · 2022: $566 · 2023: $786 · 2024: $971 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $639.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.51 | 2019-2024 | Ofev, Spiriva Respimat, Synjardy |
| Novo Nordisk INC | $608.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $567.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $506.09 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $367.75 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $281.15 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $265.94 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $246.21 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $157.56 | 2019-2025 | Ubrelvy |
| Amarin Pharma, INC. | $122.49 | 2020-2021 | |
| Exact Sciences Corporation | $106.54 | 2023-2024 | Cologuard Collection Kit |
| Seqirus USA INC | $100.42 | 2022-2024 | Flucelvax, Fluad, Fluad Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $83.56 | 2024-2025 | Rexulti |
| Sanofi Pasteur INC. | $72.90 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $69.65 | 2022-2023 | Hetlioz, Fanapt |
| Shield Therapeutics INC | $59.74 | 2024 | |
| Dynavax Technologies Corporation | $37.42 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $22.96 | 2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2021 | |
| Lucid Diagnostics INC. | $18.07 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.40 | 2025 | Voquezna |
| Eisai INC. | $16.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.23 | 2023 | Quviviq |
| Medtronic, INC. | $15.82 | 2023 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Umphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.